{
    "2020-12-07": [
        [
            {
                "time": "2021-12-05",
                "original_text": "Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305 in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at the American Society of Hematology Annual Meeting",
                "features": {
                    "keywords": [
                        "Loxo Oncology",
                        "Lilly",
                        "Phase 1/2 BRUIN",
                        "LOXO-305",
                        "Chronic Lymphocytic Leukemia",
                        "Small Lymphocytic Lymphoma"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2021-12-05",
                "original_text": "Lilly (LLY)/UnitedHealth Launch COVID-19 Study on Bamlanivimab",
                "features": {
                    "keywords": [
                        "Lilly",
                        "UnitedHealth",
                        "COVID-19",
                        "Bamlanivimab"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2021-12-05",
                "original_text": "AbCellera Biologics sets terms of IPO, which could value the company at up to $4.5 billion",
                "features": {
                    "keywords": [
                        "AbCellera Biologics",
                        "IPO",
                        "$4.5 billion"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech",
                        "investing"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-12-05",
                "original_text": "Thiel-backed therapy developer AbCellera looks to raise up to $391 mln in IPO",
                "features": {
                    "keywords": [
                        "Thiel-backed",
                        "AbCellera",
                        "therapy developer",
                        "IPO",
                        "$391 mln"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech",
                        "venture capital"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}